Proteasome inhibitors disrupt the unfolded protein response in myeloma cells

Proc Natl Acad Sci U S A. 2003 Aug 19;100(17):9946-51. doi: 10.1073/pnas.1334037100. Epub 2003 Aug 5.

Abstract

Novel agents that target the proteasome, a proteolytic complex responsible for the degradation of ubiquitinated proteins, have demonstrated remarkable therapeutic efficacy in multiple myeloma, a plasma cell malignancy. However, the mechanism by which these compounds act remains unknown. A signaling pathway called the unfolded protein response (UPR) allows cells to handle the proper folding of proteins. The transcription factor XBP-1, a regulator of the UPR, is also required for plasma cell differentiation, suggesting a link between the UPR and plasma cell differentiation. Here we show that proteasome inhibitors target XBP-1 and the UPR in myeloma cells. Proteasome inhibitors suppress the activity of the translumenal endoplasmic reticulum endoribonuclease/kinase, IRE1 alpha, to impair the generation of the active, spliced XBP-1 species and simultaneously stabilize the unspliced species that acts as a dominant negative. Myeloma cells rendered functionally deficient in XBP-1 undergo increased apoptosis in response to endoplasmic reticulum stress. Identification of compounds that target the activity of IRE1 alpha/XBP-1 may yield novel therapies for the treatment of multiple myeloma and other malignancies that rely on an intact UPR.

Publication types

  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, P.H.S.

MeSH terms

  • 3T3 Cells
  • Animals
  • Apoptosis / drug effects
  • Cysteine Endopeptidases
  • Cysteine Proteinase Inhibitors / pharmacology*
  • DNA-Binding Proteins / genetics
  • DNA-Binding Proteins / metabolism
  • Endoplasmic Reticulum / drug effects
  • Endoribonucleases
  • Humans
  • Leupeptins / pharmacology
  • Membrane Proteins*
  • Mice
  • Multienzyme Complexes / antagonists & inhibitors*
  • Multiple Myeloma / drug therapy*
  • Multiple Myeloma / genetics
  • Multiple Myeloma / metabolism*
  • Neoplasm Proteins / genetics
  • Neoplasm Proteins / metabolism
  • Proteasome Endopeptidase Complex
  • Protein Folding*
  • Protein Serine-Threonine Kinases / metabolism
  • RNA Splicing / drug effects
  • Regulatory Factor X Transcription Factors
  • Transcription Factors / genetics
  • Transcription Factors / metabolism
  • Tumor Cells, Cultured
  • Tunicamycin / pharmacology
  • X-Box Binding Protein 1

Substances

  • Cysteine Proteinase Inhibitors
  • DNA-Binding Proteins
  • Leupeptins
  • Membrane Proteins
  • Multienzyme Complexes
  • Neoplasm Proteins
  • Regulatory Factor X Transcription Factors
  • Transcription Factors
  • X-Box Binding Protein 1
  • XBP1 protein, human
  • Xbp1 protein, mouse
  • Tunicamycin
  • ERN2 protein, human
  • Ern2 protein, mouse
  • Protein Serine-Threonine Kinases
  • Endoribonucleases
  • Cysteine Endopeptidases
  • Proteasome Endopeptidase Complex
  • benzyloxycarbonylleucyl-leucyl-leucine aldehyde